Muscarinic receptor stimulation increases inositol-phospholipid metabolism and inhibits cyclic AMP accumulation in PC12 cells.
Muscarinic receptor stimulation increased the accumulation of 3H-inositol phosphates in PC12 cells whose phospholipids had been prelabeled with [3H]inositol. Muscarine also inhibited the increase in cyclic AMP (cAMP) accumulation caused by 5'-N-ethylcarboxamide adenosine or by vasoactive intestinal peptide. This effect of muscarine was apparently due to the inhibition of adenylate cyclase rather than to a stimulation of a cAMP specific phosphodiesterase. The muscarinic receptor antagonist pirenzepine inhibited both the stimulation of inositol-phospholipid metabolism and the inhibition of cAMP production with Ki values of 0.34 microM and 0.36 microM, respectively. PC12 cells contained a single class of N-[3H]methylscopolamine ([3H]NMS) binding sites. Competition studies with muscarine (KD, 15 microM) and pirenzepine (Ki, 0.12 microM) revealed no evidence for multiple muscarinic receptors. The Ki of pirenzepine for the inhibition of [3H]NMS binding and the inhibition of muscarinic actions is consistent with the possibility that this is not an M1 receptor. Muscarine inhibited cAMP accumulation in cells made deficient in protein kinase C; therefore, this protein kinase is probably not involved in mediating the inhibitory effect of muscarine. The phorbol ester 12-O-tetradecanoylphorbol 13-acetate also inhibited cAMP accumulation in PC12 cells but the mechanism of this effect differed from that of muscarine. Bradykinin caused a large increase in the accumulation of 3H-inositol phosphates and [3H]diacylglycerol relative to muscarine but did not inhibit cAMP production. Oxotremorine inhibited cAMP accumulation but it did not stimulate inositol-phospholipid metabolism.(ABSTRACT TRUNCATED AT 250 WORDS)
Horwitz
J
J
Department of Pediatrics, University of Chicago, IL 60637.
D000818:Animals; D000242:Cyclic AMP / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009116:Muscarine / Q000494:pharmacology; D019832:N-Methylscopolamine; D010673:Pheochromocytoma / Q000378:metabolism; D010703:Phorbol Esters / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010890:Pirenzepine / Q000494:pharmacology; D011493:Protein Kinase C / Q000378:metabolism; D011976:Receptors, Muscarinic / Q000502:physiology*; D012602:Scopolamine Derivatives / Q000037:antagonists & inhibitors / Q000378:metabolism; D013268:Stimulation, Chemical; D014407:Tumor Cells, Cultured
D010703:Phorbol Esters; D010716:Phosphatidylinositols; D010726:Phosphodiesterase Inhibitors; D011976:Receptors, Muscarinic; D012602:Scopolamine Derivatives; D010890:Pirenzepine; D009116:Muscarine; D000242:Cyclic AMP; D011493:Protein Kinase C; D019832:N-Methylscopolamine